{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:05:51Z","timestamp":1781305551051,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiologic role of the sympathetic nervous system activation in conditions such as hypertension and perturbed glucose homeostasis, it is pertinent to postulate that SGLT2 inhibitors may exert their beneficial effects at least in part via sympathetic inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>SGLT2 inhibitors have shown enormous potential to improve cardiovascular outcomes in patients with type 2 diabetes, and their therapeutic potential is currently being investigated in a range of associated comorbidities such as heart failure and chronic kidney disease. Indeed, recent experimental data in relevant animal models highlight a bidirectional interaction between sympathetic nervous system activation and SGLT2 expression, and this facilitates several of the features associated with SGLT2 inhibition observed in clinical trials including improved glucose metabolism, weight loss, increased diuresis, and lowering of blood pressure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Currently available data highlight the various levels of interaction between the sympathetic nervous system and SGLT2 expression and explores the potential for SGLT2 inhibition as a therapeutic strategy in conditions commonly characterised by sympathetic activation.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11906-022-01170-z","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T07:02:51Z","timestamp":1646204571000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-006X","authenticated-orcid":false,"given":"Lakshini Y.","family":"Herat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vance B.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"2","key":"1170_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S2213-8587(14)70033-6","volume":"3","author":"M Schlaich","year":"2015","unstructured":"Schlaich M, et al. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol. 2015;3(2):148\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1170_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pharmthera.2010.02.002","volume":"126","author":"GW Lambert","year":"2010","unstructured":"Lambert GW, et al. Sympathetic nervous activation in obesity and the metabolic syndrome\u2013causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126(2):159\u201372.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1170_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/nyas.14217","volume":"1454","author":"R Carnagarin","year":"2019","unstructured":"Carnagarin R, et al. Effects of sympathetic modulation in metabolic disease. Ann N Y Acad Sci. 2019;1454(1):80\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"1170_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/bph.14481","volume":"176","author":"R Carnagarin","year":"2019","unstructured":"Carnagarin R, et al. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol. 2019;176(12):1839\u201352.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1170_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11906-008-0083-1","volume":"10","author":"NE Straznicky","year":"2008","unstructured":"Straznicky NE, et al. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep. 2008;10(6):440\u20137.","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"1170_CR6","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1210\/jc.2005-0961","volume":"90","author":"NE Straznicky","year":"2005","unstructured":"Straznicky NE, et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90(11):5998\u20136005.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1170_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1463-1326.2011.01497.x","volume":"14","author":"NE Straznicky","year":"2012","unstructured":"Straznicky NE, et al. The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. Diabetes Obes Metab. 2012;14(2):139\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"1170_CR8","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation"},{"issue":"10","key":"1170_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jacc.2003.12.049","volume":"43","author":"G Schillaci","year":"2004","unstructured":"Schillaci G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43(10):1817\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1170_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000074050","volume":"13","author":"EI Sorkhou","year":"2004","unstructured":"Sorkhou EI, et al. Prevalence of metabolic syndrome among hypertensive patients attending a primary care clinic in Kuwait. Med Princ Pract. 2004;13(1):39\u201342.","journal-title":"Med Princ Pract"},{"key":"1170_CR11","doi-asserted-by":"publisher","first-page":"341583","DOI":"10.1155\/2015\/341583","volume":"2015","author":"AA Thorp","year":"2015","unstructured":"Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583.","journal-title":"J Diabetes Res"},{"issue":"6","key":"1170_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00000441-200512000-00008","volume":"330","author":"SA Morse","year":"2005","unstructured":"Morse SA, et al. Hypertension and the metabolic syndrome. Am J Med Sci. 2005;330(6):303\u201310.","journal-title":"Am J Med Sci"},{"issue":"7","key":"1170_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00125-005-1798-z","volume":"48","author":"G Grassi","year":"2005","unstructured":"Grassi G, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48(7):1359\u201365.","journal-title":"Diabetologia"},{"issue":"3","key":"1170_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/HYPERTENSIONAHA.110.155663","volume":"56","author":"E Lambert","year":"2010","unstructured":"Lambert E, et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56(3):351\u20138.","journal-title":"Hypertension"},{"issue":"18","key":"1170_CR15","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","volume":"123","author":"F Mahfoud","year":"2011","unstructured":"Mahfoud F, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940\u20136.","journal-title":"Circulation"},{"issue":"7","key":"1170_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition\u2013a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551\u20139.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1170_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"1170_CR18","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00125-020-05254-w","volume":"63","author":"G Daniele","year":"2020","unstructured":"Daniele G, et al. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. Diabetologia. 2020;63(11):2423\u201333.","journal-title":"Diabetologia"},{"issue":"4","key":"1170_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.560181","volume":"44","author":"G Musso","year":"2012","unstructured":"Musso G, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375\u201393.","journal-title":"Ann Med"},{"issue":"9","key":"1170_CR20","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1210\/jc.2018-02254","volume":"104","author":"A Yoshida","year":"2019","unstructured":"Yoshida A, et al. Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin. J Clin Endocrinol Metab. 2019;104(9):3647\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1170_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","volume":"26","author":"X Cai","year":"2018","unstructured":"Cai X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (Silver Spring). 2018;26(1):70\u201380.","journal-title":"Obesity (Silver Spring)"},{"key":"1170_CR22","doi-asserted-by":"crossref","unstructured":"Mazidi M, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc, 2017;6(6).","DOI":"10.1161\/JAHA.116.004007"},{"key":"1170_CR23","doi-asserted-by":"crossref","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2).","DOI":"10.3390\/metabo11020087"},{"key":"1170_CR24","doi-asserted-by":"publisher","first-page":"117955141986681","DOI":"10.1177\/1179551419866811","volume":"12","author":"Y Kamijo","year":"2019","unstructured":"Kamijo Y, et al. Potential impact on lipoprotein subfractions in type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419866811.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"1","key":"1170_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","volume":"17","author":"N Nasiri-Ansari","year":"2018","unstructured":"Nasiri-Ansari N, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106.","journal-title":"Cardiovasc Diabetol"},{"key":"1170_CR26","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/JIR.S309427","volume":"14","author":"Y Liu","year":"2021","unstructured":"\u2022\u2022\u00a0Liu Y, et al. Empagliflozin alleviates atherosclerosis progression by inhibiting inflammation and sympathetic activity in a normoglycemic mouse model. J Inflamm Res. 2021;14:2277\u221287. A recent pre-clinical study providing evidence of SGLT2 inhibition with empagliflozin prevents atherosclerosis by repressing inflammation and sympathetic activity.","journal-title":"J Inflamm Res"},{"key":"1170_CR27","doi-asserted-by":"publisher","first-page":"6305735","DOI":"10.1155\/2016\/6305735","volume":"2016","author":"W Leng","year":"2016","unstructured":"Leng W, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-\/-) mice. Mediators Inflamm. 2016;2016:6305735.","journal-title":"Mediators Inflamm"},{"issue":"22","key":"1170_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"19","key":"1170_CR29","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"\u2022\u2022\u00a0Fitchett D. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.\u00a0Eur Heart J. 2016;37:1526\u221234.\u00a0Clinical trial in type 2 diabetics with high cardiovascular risk, showing empagliflozin reduced cardiovascular death and hospitalization due to heart failure.","journal-title":"Eur Heart J"},{"issue":"21","key":"1170_CR30","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"issue":"8","key":"1170_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1170_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","volume":"63","author":"K Kario","year":"2020","unstructured":"Kario K, Ferdinand KC, O\u2019Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020;63(3):249\u201362.","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"1170_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2337\/dc14-1596","volume":"38","author":"C Majewski","year":"2015","unstructured":"Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38(3):429\u201330.","journal-title":"Diabetes Care"},{"issue":"1","key":"1170_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","volume":"18","author":"S Kawasoe","year":"2017","unstructured":"Kawasoe S, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"1170_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1170_CR36","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","volume":"42","author":"JE Neter","year":"2003","unstructured":"Neter JE, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878\u201384.","journal-title":"Hypertension"},{"issue":"6","key":"1170_CR37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","volume":"58","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183\u20137.","journal-title":"Diabetologia"},{"issue":"11","key":"1170_CR38","doi-asserted-by":"publisher","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","volume":"309","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889-900.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1170_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"Cherney DZI, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231\u201344.","journal-title":"Kidney Int"},{"issue":"2","key":"1170_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119\u201329.","journal-title":"Circulation"},{"issue":"1","key":"1170_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","volume":"16","author":"M Pfeifer","year":"2017","unstructured":"Pfeifer M, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1170_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han JH, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet. Diabetologia. 2017;60(2):364\u201376.","journal-title":"Diabetologia"},{"issue":"2","key":"1170_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","volume":"5","author":"LY Herat","year":"2020","unstructured":"\u2022\u2022\u00a0Herat LY, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5(2):169\u221279. First pre-clinical study using a hypertensive mouse model directly elucidating the crosstalk between the SNS and SGLT2 regulation.","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"1170_CR44","doi-asserted-by":"publisher","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11(11):e0165703.","journal-title":"PLoS ONE"},{"issue":"1\u20133","key":"1170_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1\u20133):246\u201355.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1170_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"\u2022\u2022\u00a0Tikkanen I, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u22128. The EMPA-REG BP trail was the landmark clinical study which showed the beneficial effect of Empagliflozin on BP lowering.","journal-title":"Diabetes Care"},{"issue":"4","key":"1170_CR47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262\u201375.","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"1170_CR48","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1113\/expphysiol.2009.047332","volume":"95","author":"JP Fisher","year":"2010","unstructured":"Fisher JP, Fadel PJ. Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension. Exp Physiol. 2010;95(5):572\u201380.","journal-title":"Exp Physiol"},{"issue":"10","key":"1170_CR49","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","volume":"35","author":"VB Matthews","year":"2017","unstructured":"Matthews VB, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35(10):2059\u201368.","journal-title":"J Hypertens"},{"issue":"4","key":"1170_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/nep.12620","volume":"21","author":"RH Elliott","year":"2016","unstructured":"Elliott RH, et al. Is it time to think about the sodium glucose co-transporter 2 sympathetically? Nephrology (Carlton). 2016;21(4):286\u201394.","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"1170_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.yfrne.2014.04.001","volume":"35","author":"TJ Bartness","year":"2014","unstructured":"Bartness TJ, et al. Neural innervation of white adipose tissue and the control of lipolysis. Front Neuroendocrinol. 2014;35(4):473\u201393.","journal-title":"Front Neuroendocrinol"},{"issue":"8","key":"1170_CR52","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/bph.15381","volume":"178","author":"X Yang","year":"2021","unstructured":"Yang X, et al. Inhibition of the sodium\u2013glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Br J Pharmacol. 2021;178(8):1756\u201371.","journal-title":"Br J Pharmacol"},{"key":"1170_CR53","doi-asserted-by":"crossref","unstructured":"Matthews JR, et al. SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: a novel mechanism for beiging. Biomedicines. 2020;8(11).","DOI":"10.3390\/biomedicines8110514"},{"key":"1170_CR54","doi-asserted-by":"crossref","unstructured":"Thyagarajan B, Foster MT. Beiging of white adipose tissue as a therapeutic strategy for weight loss in humans. Horm Mol Biol Clin Investig. 2017;31(2).","DOI":"10.1515\/hmbci-2017-0016"},{"issue":"3","key":"1170_CR55","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3324\/haematol.2018.192898","volume":"104","author":"A Al-Sharea","year":"2019","unstructured":"Al-Sharea A, et al. Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis. Haematologica. 2019;104(3):456\u201367.","journal-title":"Haematologica"},{"issue":"4","key":"1170_CR56","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00125-012-2817-5","volume":"56","author":"N Sattar","year":"2013","unstructured":"Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56(4):686\u201395.","journal-title":"Diabetologia"},{"issue":"4","key":"1170_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"\u2022\u2022\u00a0Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u221257. Clinical trail demonstrating that treatment with dapagliflozin reduced the rate of cardiovascular death or hospitalization due to heart failure.","journal-title":"N Engl J Med"},{"issue":"15","key":"1170_CR58","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"key":"1170_CR59","doi-asserted-by":"crossref","unstructured":"Azzam O, et al. Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opin Pharmacother. 2021:1\u20139.","DOI":"10.1080\/14656566.2021.1959915"},{"issue":"1","key":"1170_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5582\/ddt.2017.01069","volume":"12","author":"S Kiuchi","year":"2018","unstructured":"\u2022\u2022\u00a0Kiuchi S, et al. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: a case report. Drug Discov Ther. 2018;12(1):51\u22124. The first human study (case report in a patient with heart failure) highlighting that SGLT2 inhibitor mediated decrease in cardiac sympathetic nerve activity is a potential mechanism for cardio-protection.","journal-title":"Drug Discov Ther"},{"issue":"21","key":"1170_CR61","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"\u2022\u2022\u00a0McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. The landmark clinical trail DAPA-HF demonstrates that dapagliflozin prevents cardiovascular deaths and heart failure events in patients with heart failure and a reduced ejection fraction irrespective of diabetes status.","journal-title":"N Engl J Med"},{"issue":"3","key":"1170_CR62","doi-asserted-by":"publisher","first-page":"e0150756","DOI":"10.1371\/journal.pone.0150756","volume":"11","author":"Y Chiba","year":"2016","unstructured":"Chiba Y, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLoS One. 2016;11(3):e0150756.","journal-title":"PLoS ONE"},{"issue":"7","key":"1170_CR63","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/hr.2017.14","volume":"40","author":"T Yoshikawa","year":"2017","unstructured":"Yoshikawa T, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res. 2017;40(7):646\u201351.","journal-title":"Hypertens Res"},{"key":"1170_CR64","doi-asserted-by":"publisher","first-page":"l1328","DOI":"10.1136\/bmj.l1328","volume":"365","author":"G Musso","year":"2019","unstructured":"Musso G, et al. Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019;365:l1328.","journal-title":"BMJ"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-022-01170-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-022-01170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:30:57Z","timestamp":1700296257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-022-01170-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s11906-022-01170-z","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"15 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All the authors have seen and approved the manuscript and consented to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Lakshini Y. Herat, Jennifer Matthews, Omar Azzam and Vance B. Matthews declare that they have no conflict of interest. Markus P. Schlaich reports grants from Boehringer Ingelheim, while conducting the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does contain studies with human or animal subjects performed by some of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}